Neurocrine Biosciences (NBIX) Deferred Taxes (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Deferred Taxes for 16 consecutive years, with -$25.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Deferred Taxes rose 32.35% year-over-year to -$25.3 million; the trailing twelve-month figure through Jun 2026 stood at $130.1 million (up 210.91% YoY), and the FY2025 full-year result was $165.4 million, up 234.36% from the prior year.
• Deferred Taxes climbed to -$25.3 million in Q2 2026 per NBIX's latest filing, from -$61.1 million in the prior quarter.
• Across five years, Deferred Taxes topped out at $168.3 million in Q3 2025 and bottomed at -$61.1 million in Q1 2026.
• Historically, Deferred Taxes has averaged -$4.5 million across 5 years, with a median of -$14.6 million in 2024.
• The sharpest annual moves came in 2023 and 2025: Deferred Taxes plunged 10433.33% in 2023, then jumped 582.23% in 2025.
• Over 5 years, Deferred Taxes stood at $13.5 million in 2022, then jumped by 52.59% to $20.6 million in 2023, then slumped by 251.94% to -$31.3 million in 2024, then surged by 253.99% to $48.2 million in 2025, then tumbled by 152.49% to -$25.3 million in 2026.
• According to Business Quant data, Deferred Taxes over the past three periods registered -$25.3 million, -$61.1 million, and $48.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.